Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.8K
Ligand Binding Sites02:40

Ligand Binding Sites

14.8K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
14.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction notice to "Gene regulation by antisense transcription: A focus on neurological and cancer diseases" [Biomedicine & Pharmacotherapy 145 (2022) 112265].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Exploration of Novel Antimicrobial Peptides from Gut Probiotics Enterococcus spp. Against Extensively drug-resistant Pathogens Through cutting-edge Computational Discovery.

Probiotics and antimicrobial proteins·2026
Same author

Vancomycin Insights: An Update on Mechanism, Activity, Toxicity, Resistance, and Novel Drug Delivery Systems.

Iranian journal of pharmaceutical research : IJPR·2025
Same author

Antimicrobial activity of partially purified polysaccharide extract of Arthrospira platensis PCST5.

FEMS microbiology letters·2025
Same author

Comparing the Soluble Form of Recombinant Human Insulin-like Growth Factor-1 (rhIGF-1) in <i>Escherichia coli</i> Using Thioredoxin as Fused and Co-expressed Protein.

Protein and peptide letters·2024
Same author

Design and Evaluation of a Novel Anti-microbial Peptide from Cathelicidin-2: Selectively Active Against <i>Acinetobacter baumannii</i>.

Iranian journal of pharmaceutical research : IJPR·2024

Related Experiment Video

Updated: Jan 9, 2026

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
08:40

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

Published on: March 14, 2016

20.1K

Design, Expression, and Binding Interactions Study of the Recombinant Engineered IL-6R.

Elham Mehdizadeh Marzenaki1, Mojgan Bandehpour2,3, Adel Haghighi4

  • 1Department of Molecular Medicine, School of Advanced Technologies, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Iranian Journal of Pharmaceutical Research : IJPR
|December 8, 2025
PubMed
Summary
This summary is machine-generated.

Engineered interleukin-6 receptor (IL-6R) fragments were designed to reduce binding to glycoprotein 130 (gp130). This engineered protein shows potential as a cost-effective therapeutic for IL-6-related diseases.

Keywords:
Autoimmune DiseasesIL-6Molecular DockingRecombinant Protein Expression

More Related Videos

A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

8.1K
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.5K

Related Experiment Videos

Last Updated: Jan 9, 2026

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
08:40

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions

Published on: March 14, 2016

20.1K
A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

8.1K
Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

8.5K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Structural Biology

Background:

  • Soluble interleukin-6 receptor (IL-6R) trans-signaling is implicated in chronic inflammatory diseases, autoimmune disorders, and cancers.
  • Targeting the IL-6R-gp130 interaction is a key strategy for managing these IL-6-mediated pathologies.

Purpose of the Study:

  • To computationally model and engineer a fragment of IL-6R (residues 121-300) to reduce its binding affinity to glycoprotein 130 (gp130).
  • To express and characterize the engineered IL-6R fragment (seIL-6R) for potential therapeutic applications.

Main Methods:

  • Protein engineering and molecular modeling using AlphaFold and ClusPro for docking simulations.
  • Recombinant expression of seIL-6R in Chinese hamster ovary (CHO)-K1 cells.
  • Biochemical and biophysical characterization including Western blotting and Fourier transform infrared (FTIR) spectroscopy.

Main Results:

  • The engineered seIL-6R fragment exhibited improved stability, solubility, and a reduced molecular weight (20.6 kDa).
  • Molecular docking predicted a diminished binding interaction between seIL-6R and gp130.
  • Western blotting confirmed successful recombinant protein expression, and FTIR analysis verified the preservation of secondary structure.

Conclusions:

  • The engineered seIL-6R protein demonstrates favorable physicochemical properties and reduced binding to gp130.
  • This engineered protein represents a promising candidate for further development as a therapeutic agent against IL-6-driven diseases.